Traumatic brain injury does its damage in two waves: the impact itself, and a slower cascade of inflammation, swelling and cell death that follows over hours and days. That second wave is why researchers have tested TUDCA, a bile acid that reduces apoptosis and ER stress in many laboratory models. In a 2025 rat study, a single intravenous dose given 30 minutes after injury reduced brain lesion volume and swelling on MRI [1]. A mouse study the same year reported improved behavior and less neuroinflammation [2]. Related work in brain bleeds found similar protection in rodents [3]. But every one of these results comes from animals, the studies that report a route injected TUDCA, often before or shortly after the injury, and one widely cited TBI study was retracted in 2026 [4]. No human trial of TUDCA for brain injury has been published. This page covers what each study tested and why none of it supports treating a head injury yourself.
Key Takeaways
- In rats with a controlled cortical impact injury, intravenous TUDCA at 300 mg/kg given 30 minutes after injury reduced lesion volume on days 1 and 7 and lowered an anxiety measure on day 7, with 10 treated and 12 control animals [1].
- A 2025 mouse study reported that TUDCA improved behavioral deficits after TBI and reduced neuroinflammation through the STING and NF-κB/NLRP3 pathways [2].
- A 2017 TBI study of TUDCA and the Akt pathway was retracted in 2026; the retraction notice gives no reason [4].
- In subarachnoid hemorrhage models, TUDCA given by internal carotid injection [5] or as a three-day pretreatment before the bleed [3] reduced brain swelling or cell death and improved neurological scores.
- A 2016 review concluded there were no published data supporting improved clinical outcomes of TBI with TUDCA [6], and no human trial has been published since.
Why TUDCA Is Studied After Brain Injury
The first moments of a traumatic brain injury tear and crush tissue, and nothing given afterward can undo that. The secondary injury is different. Over the following hours and days, damaged tissue swells, inflammatory signals recruit immune cells, the blood-brain barrier leaks, and neurons near the injury die through programmed pathways such as apoptosis and pyroptosis. Much of brain injury research aims at this secondary phase because it is, in principle, open to treatment.
TUDCA enters this research because of its laboratory profile. A 2016 review in Neurocritical Care surveyed preclinical work showing that TUDCA inhibits several proteins involved in apoptosis, supports cell survival pathways and has anti-inflammatory effects in models of neuroinflammation [6]. The reviewers argued these mechanisms could apply to TBI. They also stated plainly that there were no published data supporting improvement in clinical outcomes of TBI with TUDCA [6]. That remains true.
The Traumatic Brain Injury Studies
Lesion size and swelling in rats. The most clearly reported TBI study used a controlled cortical impact, a device that strikes the exposed brain with a set force [1]. Male rats were randomized to sham treatment (12 animals) or an intravenous infusion of TUDCA at 300 mg/kg (10 animals) 30 minutes after injury. MRI on days 1 and 7 showed smaller lesion volumes in the TUDCA group, and the control group had more cytotoxic edema on day 1. On day 7, the treated rats scored lower on an anxiety index in an elevated plus maze [1]. The authors were careful about limits: a dose-response relationship and the best treatment window still need to be determined, and future studies should test repeated dosing in both sexes.
Neuroinflammation in mice. A second 2025 study reported that TUDCA improved behavioral deficits caused by TBI in mice and reduced neuronal injury and inflammation [2]. In cell experiments, it blocked STING and NF-κB/NLRP3 signaling that drives pyroptosis, an inflammatory form of cell death, and the authors proposed that TUDCA binds directly to the STING protein [2]. The abstract does not give the dose or route used in the animals, so it cannot be compared with any oral amount.
A retracted study. A 2017 mouse TBI paper reported that TUDCA reduced ER stress, brain swelling and neurological deficits through the Akt pathway. Frontiers in Cellular Neuroscience retracted it in 2026 [4]. The retraction notice in PubMed gives no reason, and it would be speculation to supply one. What matters for a reader is that this paper should no longer be counted as evidence, and older articles that cite it as support for TUDCA after head injury are relying on a withdrawn result.
Brain Bleed Studies: Subarachnoid and Intracerebral Hemorrhage
Bleeding into or around the brain causes a similar secondary injury, and TUDCA has been tested there too. In a rat model of subarachnoid hemorrhage, bleeding into the space around the brain, TUDCA given by internal carotid injection reduced brain water content and improved neurological scores at 24 and 72 hours [5]. It also prevented the fall in the survival proteins SIRT3 and BCL-2 and the rise in BAX and cleaved caspase-3. When the researchers silenced the bile acid receptor TGR5, the protective effect at 24 hours disappeared [5].
A mouse study of the same condition gave TUDCA at 500 mg/kg per day for three days before inducing the bleed [3]. Pretreated mice had better cerebral blood flow, less blood-brain barrier leakage, lower ER stress signaling through the PERK/eIF2α/ATF4/CHOP pathway, less caspase-12-dependent apoptosis and better neurological function [3]. Pretreatment is a useful experimental tool, but nobody can take a drug three days before an unexpected brain bleed, so this design says little about treatment after the event.
For intracerebral hemorrhage, bleeding inside the brain tissue, a 2003 rat study is the one most often cited: TUDCA given before or up to six hours after a collagenase-induced bleed reduced lesion volume at two days by as much as 50% and improved several movement tests [7]. Our page on TUDCA and apoptosis covers that study and its mechanism in more detail.
Not Every Brain Study Is Positive
Neuroprotection results in rodents have a long history of not holding up, and TUDCA is not exempt. A 2026 study set out to reassess TUDCA in two mouse models of ischemic stroke, where a blocked artery rather than an impact or bleed causes the damage [8]. Intravenous TUDCA at 100 mg/kg, given one hour before or after the stroke, did not reduce infarct size, did not improve neurological scores and did not reduce blood-brain barrier leakage. It also failed to protect a human stem cell-derived blood-brain barrier model on a chip [8].
Ischemic stroke is a different injury from TBI, so this result does not cancel the TBI findings. It does show that the protective effects reported in single studies are not guaranteed to replicate when another group tests them under different conditions, and the TBI work has not yet been independently repeated with the same model and dose.
What This Means After a Head Injury
A head injury or a suspected brain bleed is a medical emergency. Warning signs such as worsening headache, repeated vomiting, confusion, unusual drowsiness, weakness, slurred speech or a seizure need emergency assessment, and nothing on this page supports treating a head injury yourself. The animal studies above that report a route gave TUDCA by vein or artery at doses chosen for rodents, usually within minutes to hours of the injury or before it. Those conditions cannot be reproduced with a supplement taken at home.
For people recovering from a TBI who are curious about TUDCA, the honest position is that it is an experimental idea with encouraging but limited rodent data, one retracted paper and no human evidence. TUDCA also has interactions and contraindications that matter for people taking other medications, which our drug interactions page covers. Any supplement during brain injury recovery is a conversation to have with the neurology or rehabilitation team rather than a decision to make alone.
Bottom Line
In rodent models, intravenous TUDCA reduced lesion volume and swelling after a cortical impact [1], reduced neuroinflammation after TBI [2], and protected the brain after subarachnoid hemorrhage when given by carotid injection [5] or as pretreatment [3]. One TBI paper was retracted in 2026 [4], a 2026 ischemic stroke study found no benefit [8], and a review found no data on clinical outcomes in TBI patients [6]. There is no human evidence that TUDCA helps after a brain injury, and a head injury needs medical care, not a supplement.
Frequently Asked Questions
Does TUDCA help with traumatic brain injury?
It has only been tested in rodents. Intravenous TUDCA given 30 minutes after injury reduced lesion volume in rats [1], and a mouse study reported less neuroinflammation [2]. No human study exists, and a review found no data supporting better clinical outcomes in TBI patients [6].
Was a TUDCA brain injury study retracted?
Yes. A 2017 Frontiers in Cellular Neuroscience paper reporting that TUDCA attenuated early brain injury through the Akt pathway was retracted in 2026. The retraction notice gives no reason [4], but the paper should no longer be counted as evidence.
Should I take TUDCA after a concussion or head injury?
Nothing in this research supports it. The animal studies gave TUDCA within minutes to hours of the injury, or in one brain bleed model as a three-day pretreatment before it [3], and the ones that state a route injected it. A head injury with worsening symptoms needs emergency care, and any supplement during recovery should be discussed with your treating team.
References
- Cáceres E, et al. Tauroursodeoxycholic acid reduces brain lesion volume and cortical edema in a rat model of Traumatic brain injury. Brain Research (2025). PMID 40490087
- Xu J, et al. Tauroursodeoxycholic acid modulates neuroinflammation via STING/NF-κB inhibition after traumatic brain injury. International Immunopharmacology (2025). PMID 40915187
- Chen X, et al. Tauroursodeoxycholic acid prevents ER stress-induced apoptosis and improves cerebral and vascular function in mice subjected to subarachnoid hemorrhage. Brain Research (2020). PMID 31778648
- Frontiers Editorial Office. Retraction: Administration of tauroursodeoxycholic acid attenuates early brain injury via Akt pathway activation. Frontiers in Cellular Neuroscience (2026). PMID 42253448
- Wu H, et al. Tauroursodeoxycholic acid attenuates neuronal apoptosis via the TGR5/SIRT3 pathway after subarachnoid hemorrhage in rats. Biological Research (2020). PMID 33261652
- Gronbeck KR, et al. Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury? Neurocritical Care (2016). PMID 26759227
- Rodrigues CM, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proceedings of the National Academy of Sciences of the United States of America (2003). PMID 12721362
- Mousavi SM, et al. Reassessment of Neuroprotective Efficacy of TUDCA in Ischemic Stroke: A Multi-Model In Vivo and In Vitro Study. International Journal of Molecular Sciences (2026). PMID 42883946
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.